Predictors of Success and Risk Factors for Attrition in the Use of Intracavernous Injection
- 1 May 1997
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 157 (5), 1681-1686
- https://doi.org/10.1016/s0022-5347(01)64834-1
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Efficacy and Safety of Intracavernosal Alprostadil in Men with Erectile DysfunctionThe New England Journal of Medicine, 1996
- High attrition rate with intracavernousinjection of prostaglandin E1 for impotencyUrology, 1994
- Objective Double-Blind Evaluation of Erectile Function with Intracorporeal Papaverine in Combination with Phentolamine and/or Prostaglandin E1Journal of Urology, 1992
- An Improved Vasoactive Drug Combination for a Pharmacological Erection ProgramJournal of Urology, 1991
- Intracavernous Injection of Prostagland in E1 in combination With Papaverine: Enhanced Effectiveness in Comparison With Papaverine Plus Phentolamine and Prostaglandin E1 AloneJournal of Urology, 1991
- Treatment of Impotence by Intrapenile Injections. A Comparison of Papaverine versus Papaverine and Phentolamine: A Double-Blind, Crossover TrialJournal of Urology, 1989
- Experience in the Management of Erectile Dysfunction Using the Intracavernosal Self-Injection of Vasoactive DrugsJournal of Urology, 1988
- Erectile Responses to Intracavernous Papaverine and Phentolamine: Comparison of Single and Combined DeliveryJournal of Urology, 1988
- Chronic Papaverine Treatment: The Effect of Repeated Injections on the Simian Erectile Response and Penile TissueJournal of Urology, 1987
- Induction of penile erection by intracavernosal injection: A double-blind comparison of phenoxybenzamineversus papaverine-phentolamineversus salineArchives of Sexual Behavior, 1987